{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T04:07:32Z","timestamp":1750910852040,"version":"3.41.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024679","name":"Advanz Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024679","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jgar.2025.04.021","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T05:01:58Z","timestamp":1746075718000},"page":"213-219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The use of ceftobiprole in treatment pathways in Spain: An expert panel review"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6394-5728","authenticated-orcid":false,"given":"Carmen","family":"Hidalgo-Tenorio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5330-5540","authenticated-orcid":false,"given":"Francisco Javier","family":"Membrillo de Novales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8571-2124","authenticated-orcid":false,"given":"Miguel","family":"Salavert Lleti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5795-0814","authenticated-orcid":false,"given":"Laura","family":"Morata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8586-4614","authenticated-orcid":false,"given":"Maria Rosa","family":"Oltra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngel","family":"Estella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Nicol\u00e1s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Luisa","family":"Pedro-Botet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andima","family":"Basterretxea Ozamiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Lora-Tamayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2025.04.021_bib0001","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jgar.2021.07.012","article-title":"Surveillance of ceftobiprole against Gram-positive and Gram-negative clinical isolates from 2018 from different European territories","volume":"26","author":"Hawser","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2025.04.021_bib0002","series-title":"Expert Review of Anti-Infective Therapy","first-page":"689","article-title":"Ceftobiprole: drug evaluation and place in therapy","author":"Giacobbe","year":"2019"},{"year":"2023","series-title":"Zevtera Ficha T\u00e9cnica","author":"Correvio","key":"10.1016\/j.jgar.2025.04.021_bib0003"},{"key":"10.1016\/j.jgar.2025.04.021_bib0004","unstructured":"US Food and Drug Administration (FDA) approves new antibiotic for three different uses | FDA [Internet]. [cited 3 May 3, 2024]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-antibiotic-three-different-uses"},{"key":"10.1016\/j.jgar.2025.04.021_bib0005","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.eimc.2021.05.002","article-title":"Ceftobiprole, a new option for multidrug resistant microorganisms in the outpatient antimicrobial therapy setting","volume":"40","author":"L\u00f3pez-Cort\u00e9s","year":"2022","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.jgar.2025.04.021_bib0006","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/jac\/dkm492","article-title":"In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent Gram-positive and Gram-negative isolates of European origin","volume":"61","author":"Pillar","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.04.021_bib0007","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijantimicag.2013.09.013","article-title":"Evaluation of the in vitro activities of ceftobiprole and comparators in staphylococcal colony or microtitre plate biofilm assays","volume":"43","author":"Abbanat","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2025.04.021_bib0008","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/ciu219","article-title":"A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia","volume":"59","author":"Awad","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.04.021_bib0009","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijantimicag.2011.11.005","article-title":"A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation","volume":"39","author":"Nicholson","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2025.04.021_bib0010","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1086\/526527","article-title":"A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections","volume":"46","author":"Noel","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.04.021_bib0011","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1056\/NEJMoa2300220","article-title":"Ceftobiprole for treatment of complicated Staphylococcus aureus bacteremia","volume":"389","author":"Holland","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2025.04.021_bib0012","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3390\/antibiotics12071218","article-title":"Cefto real-life study: real-world data on the use of Ceftobiprole in a multicenter Spanish cohort","volume":"12","author":"Hidalgo-Tenorio","year":"2023","journal-title":"Antibiotics"},{"key":"10.1016\/j.jgar.2025.04.021_bib0013","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.3390\/antibiotics12121692","article-title":"Ceft-to-Ceft study: real-life experience with ceftaroline and ceftobiprole in treatment of the principal infectious syndromes in a Spanish multicenter hospital cohort","volume":"12","author":"Arn\u00e9s Garc\u00eda","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2025.04.021_bib0014","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.3389\/fmicb.2018.01256","article-title":"In vitro activity of Tedizolid, Dalbavancin, and Ceftobiprole against Clostridium difficile","volume":"9","author":"Binyamin","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jgar.2025.04.021_bib0015","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/mdr.2014.0307","article-title":"Genotypic characterization of methicillin-resistant Staphylococcus aureus recovered at baseline from phase 3 pneumonia clinical trials for Ceftobiprole","volume":"22","author":"Mendes","year":"2016","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jgar.2025.04.021_bib0016","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/1120009X.2020.1821486","article-title":"Ceftobiprole and pneumonia in adults admitted to the emergency department is it time to assess a new therapeutic algorithm?","volume":"33","author":"Crapis","year":"2021","journal-title":"J Chemother"},{"key":"10.1016\/j.jgar.2025.04.021_bib0017","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jinf.2020.10.032","article-title":"Methicillin-susceptible staphylococcus aureus in community-acquired pneumonia: risk factors and outcomes","volume":"82","author":"Cilloniz","year":"2021","journal-title":"J Infect"},{"key":"10.1016\/j.jgar.2025.04.021_bib0018","unstructured":"Hospital-Acquired Pneumonia - Pulmonary Disorders - MSD Manual Professional Edition [Internet]. [cited 3 May 2024]. Available from: https:\/\/www.msdmanuals.com\/en-gb\/professional\/pulmonary-disorders\/pneumonia\/hospital-acquired-pneumonia."},{"key":"10.1016\/j.jgar.2025.04.021_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antibiotics10020170","article-title":"Ceftobiprole perspective: current and potential future indications","volume":"10","author":"Lupia","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.jgar.2025.04.021_bib0020","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/INF.0000000000003296","article-title":"Pharmacokinetics and safety of ceftobiprole in pediatric patients","volume":"40","author":"Rubino","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jgar.2025.04.021_bib0021","doi-asserted-by":"crossref","first-page":"E1507","DOI":"10.1093\/cid\/ciaa974","article-title":"Ceftobiprole compared with Vancomycin plus Aztreonam in the treatment of acute bacterial skin and skin structure infections: results of a phase 3, randomized, double-blind trial (TARGET)","volume":"73","author":"Overcash","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.04.021_bib0022","article-title":"Clinical practice recommendations for infectious disease management of diabetic foot infection (DFI) \u2013 2023 SPILF","volume":"54","author":"Bonnet","year":"2024","journal-title":"Infect Dis Now"},{"key":"10.1016\/j.jgar.2025.04.021_bib0023","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3390\/antibiotics12050900","article-title":"In vitro activities of Ceftobiprole, Dalbavancin, Tedizolid and comparators against clinical isolates of methicillin-resistant Staphylococcus aureus associated with skin and soft tissue infections","volume":"12","author":"Maraki","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2025.04.021_bib0024","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cmi.2016.05.004","article-title":"Time trends in the aetiology of prosthetic joint infections: a multicentre cohort study","volume":"22","author":"Benito","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2025.04.021_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2022.115713","article-title":"Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020","volume":"103","author":"Duncan","year":"2022","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2025.04.021_bib0026","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s10096-018-3295-6","article-title":"Comparative activity of ceftobiprole against coagulase-negative staphylococci from the BSAC Bacteraemia Surveillance Programme, 2013\u20132015","volume":"37","author":"Santerre Henriksen","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2025.04.021_bib0027","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eimc.2016.08.012","article-title":"Executive summary of management of prosthetic joint infections. Clinical practice guidelines by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)","volume":"35","author":"Ariza","year":"2017","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.jgar.2025.04.021_bib0028","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/1440-1681.13066","article-title":"Vancomycin dosing, monitoring and toxicity: critical review of the clinical practice","volume":"46","author":"Zamoner","year":"2019","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.jgar.2025.04.021_bib0029","article-title":"Safety and efficacy of prolonged use of Dalbavancin in bone and joint infections","volume":"63","author":"Morata","year":"2019","journal-title":"Antimicrob Agents Chemother [Internet]"},{"key":"10.1016\/j.jgar.2025.04.021_bib0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12941-020-00351-5","article-title":"Ceftobiprole: a potential empirical post-operative monotherapy in prosthetic joint infections","volume":"19","author":"Duployez","year":"2020","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.jgar.2025.04.021_bib0031","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1093\/jac\/dku236","article-title":"Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes","volume":"69","author":"Barber","year":"2014","journal-title":"J Antimicrob Chemother [Internet]"},{"key":"10.1016\/j.jgar.2025.04.021_bib0032","article-title":"Diagnosis and treatment of bacteremia and endocarditis due to Staphylococcus aureus. A clinical guideline from the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC)","volume":"33","author":"Gudiol","year":"2015","journal-title":"Enferm Infecc Microbiol Clin [Internet]"},{"key":"10.1016\/j.jgar.2025.04.021_bib0033","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12879-020-4895-1","article-title":"Clinical and prognostic differences between methicillin-resistant and methicillin-susceptible Staphylococcus aureus infective endocarditis","volume":"20","author":"Hidalgo-Tenorio","year":"2020","journal-title":"BMC Infect Dis [Internet]"},{"key":"10.1016\/j.jgar.2025.04.021_bib0034","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jacc.2019.11.047","article-title":"A contemporary picture of enterococcal endocarditis","volume":"75","author":"Peric\u00e0s","year":"2020","journal-title":"J Am Coll Cardiol [Internet]"},{"key":"10.1016\/j.jgar.2025.04.021_bib0035","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1128\/AAC.00131-07","article-title":"Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including \u03b2-lactamase-producing and vancomycin-resistant isolates","volume":"51","author":"Arias","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.04.021_bib0036","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1128\/AAC.00886-09","article-title":"Ceftobiprole is superior to Vancomycin, Daptomycin, and Linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus","volume":"54","author":"Tattevin","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.04.021_bib0037","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/cid\/ciy064","article-title":"A review of combination antimicrobial therapy for Enterococcus faecalis bloodstream infections and infective endocarditis","volume":"67","author":"Beganovic","year":"2018","journal-title":"Clin Infect Dis [Internet]"},{"key":"10.1016\/j.jgar.2025.04.021_bib0038","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3390\/antibiotics12050879","article-title":"Ampicillin and ceftobiprole combination for the treatment of Enterococcus faecalis invasive infections: \u201cthe times they are A-Changin.\u201d","volume":"12","author":"Giuliano","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2025.04.021_bib0039","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.diagmicrobio.2019.01.015","article-title":"Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016\u20132017)","volume":"94","author":"Pfaller","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2025.04.021_bib0040","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae123","article-title":"The positioning of ceftobiprole in Staphylococcus aureus bacteremia","author":"Membrillo de Novales","year":"2024","journal-title":"Clin Infect Dis [Internet]"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525000852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525000852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T16:18:32Z","timestamp":1750868312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716525000852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":40,"alternative-id":["S2213716525000852"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2025.04.021","relation":{},"ISSN":["2213-7165"],"issn-type":[{"type":"print","value":"2213-7165"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The use of ceftobiprole in treatment pathways in Spain: An expert panel review","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2025.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}